AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 50(4_Suppl), 1994, pp. 66-74
Copyright © 1994 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chulay, J.
Right arrow Articles by Young, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chulay, J.
Right arrow Articles by Young, J.

American Society of Tropical Medicine and Hygiene Symposium: Strategy for Plasmodium falciparum Vaccine Development and Clinical Trials: Panel Discussion

Jeffrey Chulay, Chairman
U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland

Raphael Mannino, Panelist
University of Medicine and Dentistry of New Jersey, Newark, New Jersey

Peter Reeve, Panelist
Special Program for Research and Training in Tropical Medicine, UNDP/World Bank/WHO, Geneva, Switzerland

William Weidanz, Panelist
University of Wisconsin, Madison, Wisconsin

James Young, Panelist
Medimmune, Inc., Gaithersburg, Maryland

In addition to the panelists, several of the symposium speakers participated in the discussion. Other participants from the floor were Ross Coppel (Walter and Eliza Hall Institute, Melbourne, Australia), Robert Desowitz (University of Hawaii, Honolulu, Hawaii), Arnold Satterthwait (Research Instituteof Scripps Clinic, La Jolla, California), Allan Saul (Queensland Institute of Medical Research, Brisbane, Australia), Joseph Cohen (Smith Kline Beecham, Rixensart, Belgium), Margaret Pinder (IIRSDA Abidjan, Cote d'Ivoire).

Antigen Selection. Dr. Chulay: I would like to start by asking Dr. Peter Reeve to comment on the proposed antigen selection strategy that Dr. Russell Howard described.

Dr. Reeve: For several reasons, I regard the selection of antigens for development into experimental vaccines for human trials to be the most important step in vaccine development. First, it implies commitment of significant resources, including funds. In industry this decision is reviewed at the very highest levels. It also makes a very visible statement of intent: expectations are therefore likely to be high.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Society of Tropical Medicine and Hygiene.